A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Lecchi M, Verderio P, Cappelletti V, De Santis F, Paolini B, Monica M, Sangaletti S, Pupa SM, Iorio MV, Bianchi G, Gennaro M, Fucà G, De Braud F, Tagliabue E, Di Nicola M.
Lecchi M, et al. Among authors: cappelletti v.
Mol Oncol. 2021 May;15(5):1345-1357. doi: 10.1002/1878-0261.12912. Epub 2021 Feb 19.
Mol Oncol. 2021.
PMID: 33523584
Free PMC article.